Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M

Aug. 09, 2022 7:34 AM ETIntra-Cellular Therapies, Inc. (ITCI)By: Meghavi Singh, SA News Editor1 Comment
  • Intra-Cellular Therapies press release (NASDAQ:ITCI): Q2 GAAP EPS of -$0.92 misses by $0.15.
  • Revenue of $55.6M (+177.3% Y/Y) beats by $6.98M.
  • Cash, cash equivalents, restricted cash and investment securities totaled $679.2M at June 30, 2022, compared to $413.7M at December 31, 2021.
  • CAPLYTA net product revenues for the second quarter 2022 were $55.1M, representing a 190% increase over the same period in 2021 and a 58% increase over the first quarter 2022.
  • Second quarter 2022 CAPLYTA new and total prescriptions increased 225% and 191%, respectively, versus the same period in 2021.
  • Second quarter 2022 CAPLYTA new and total prescriptions increased 55% and 51%, respectively, versus the first quarter 2022.

Recommended For You

Comments (1)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.